• Rajasthan

    Cong 99
    BJP 73
    RLM 3
    OTH 24
  • Madhya Pradesh

    Cong 113
    BJP 110
    BSP 2
    OTH 5
  • Chhattisgarh

    Cong 68
    BJP 15
    JCC 7
    OTH 0
  • Telangana

    TRS-AIMIM 95
    TDP-Cong 21
    BJP 1
    OTH 2
  • Mizoram

    MNF 26
    Cong 5
    BJP 1
    OTH 8

* Total Tally Reflects Leads + Wins

Aurobindo Pharma set to acquire US nutritional supplements maker Natrol for $133 mn

By: | Updated: November 12, 2014 4:19 PM

Buyout of Natrol would provide right platform for Aurobindo to create a fully-integrated OTC platform in the US.

Aurobindo says the deal with Natrol, which sells vitamins and supplements as well as diet and weight management products, will help the company expand its OTC business in the US.Aurobindo says the deal with Natrol, which sells vitamins and supplements as well as diet and weight management products, will help the company expand its OTC business in the US.

Aurobindo Pharma is all set to acquire troubled US-based nutritional supplement maker, Natrol Inc for USD 132.5 million (over Rs 810 crore) after emerging as the highest bidder for acquisition.

Aurobindo Pharma USA Inc, a subsidiary of the Hyderabad-based firm, has emerged as the highest bidder for acquisition of Natrol Inc and other affiliate entities, under a process to be finally approved by the United States Bankruptcy Court for the District of Delaware.

“Under the auction process, Aurobindo USA emerged as the highest and best bidder with a bid of USD 132.5 million to acquire the assets of Natrol with an agreement to take on certain liabilities,” Aurobindo Pharma said in a statement.

The buyout of Natrol would provide the right platform for creating a fully-integrated OTC platform in the US and other international markets, it added.

Natrol, which manufactures and sells nutritional supplements in US and other international markets, provides Aurobindo with strong brand reputation and presence in a variety of attractive supplement markets, it said.

“This acquisition is subject to final approval by the US court and other statutory approvals as may be required, including any termination of the waiting period or approval under the HSR Act, and closing conditions as per the Asset Purchase Agreement,” Aurobindo Pharma said.

Barclays acted as the sole financial advisor and Sullivan & Cromwell LLP acted as the legal counsel to Aurobindo USA, it added.

Aurobindo Pharma shares were trading at Rs 1,066 apiece on the BSE, up 3.69 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition